Loading clinical trials...
Loading clinical trials...
Investigation of a Tear-based, Lab-developed Biological Test for Breast Cancer, as a Supplemental Tool to Current Screening Recommendations for Women With Dense Breast Tissue.
Investigation of a tear-based, lab-developed biological test for breast cancer, as a supplemental tool to current screening recommendations for women with dense breast tissue will explore if a tear-based biological test can be used as a support tool in the breast cancer screening protocol for women with dense breast tissue. The test was designed and validated by Namida Lab, Inc., a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified lab.
Age
18 - 100 years
Sex
FEMALE
Healthy Volunteers
No
Namida Lab
Fayetteville, Arkansas, United States
Start Date
October 1, 2021
Primary Completion Date
October 1, 2024
Completion Date
October 1, 2024
Last Updated
December 11, 2023
1,500
ESTIMATED participants
Schirmer Strip
DIAGNOSTIC_TEST
Lead Sponsor
Namida Lab
NCT06934239
NCT07472036
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions